Table 1.

Clinical characteristics and 2677G>T/A genotype distribution of the AOCS cohort

Cases (n = 309)2677G>T/A genotypes*
P
GG (n = 91)GA/GT (n = 141)TT/TA (n = 68)
Median age (range)58.4 (31.3-80.5)58.3 (35.5-78.5)58.5 (35.5-78.5)58.5 (42.7-76.5)0.4
Primary site
    Ovary262 (84.8)76 (83.5)116 (82.3)63 (92.6)0.3
    Fallopian tube12 (3.9)3 (3.3)7 (4.5)2 (2.9)
    Peritoneal35 (11.3)12 (13.2)18 (12.8)3 (4.4)
FIGO stage
    I42 (13.6)7 (7.7)20 (14.2)13 (19.1)0.5
    II25 (8.1)7 (7.7)12 (8.5)5 (7.3)
    III212 (68.6)68 (74.7)94 (66.7)45 (66.2)
    IV30 (9.7)9 (9.9)15 (10.6)5 (7.34
Histology
    Serous217 (70.2)66 (72.5)98 (69.5)46 (67.7)0.7
    Clear cell27 (8.7)8 (8.8)12 (8.5)6 (8.8)
    Endometrioid22 (7.1)4 (4.4)10 (7.1)7 (10.3)
    MMMT13 (4.2)7 (7.7)4 (2.8)2 (2.9)
    Mucinous6 (1.9)1 (1.1)4 (2.8)1 (1.5)
    Other24 (7.8)5 (5.5)13 (9.3)6 (8.8)
Residual disease
    Nil/microscopic133 (43.1)36 (39.6)67 (47.5)27 (39.7)0.2
    ≤1 cm94 (30.4)27 (29.7)43 (30.5)20 (29.4)
    >1 to ≤2 cm14 (4.5)4 (4.4)6 (4.3)4 (5.9)
    >2 cm47 (15.2)13 (14.3)22 (15.6)11 (16.2)
    Macroscopic, size unknown21 (6.8)11 (12.0)3 (2.1)6 (8.8)
  • Abbreviation: MMMT, malignant mullerian mixed tumor.

  • * n does not sum to 309 because of missing genotype data.

  • P values are based on χ2 test for significant differences in frequencies between genotypes.